Ipsen Updates Executive Committee

Ipsen, a global specialty care biopharmaceutical company, has made the following changes to its Executive Committee:

• Mari Scheiffele is appointed to EVP, Chief Product Officer
• Andreas Gerber is appointed to EVP, Head of International
• Caroline Sitbon is appointed to EVP, General Counsel

Scheiffele, Gerber, and Sitbon will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025.

“These three appointments bring additional highly qualified global leaders to our executive leadership team and I’m delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,” said David Loew. “After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets.”

About Mari Scheiffele

After four years leading the commercial operations for the International Region at Ipsen, Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Scheiffele will focus on driving product development and pipeline innovation for new medicines and lead global brands and life cycle management. She succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen.

About Andreas Gerber

Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Gerber will lead Ipsen’s operations in all geographies excluding North America. His business acumen and commercial operations experience will support driving growth in Ipsen’s three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele.

About Caroline Sitbon

Finally, Sitbon has been promoted to the role of Ipsen’s General Counsel. She joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Sitbon will lead legal and business ethics and will also serve as the Board of Directors’ General Secretary. She succeeds François Garnier, who will be retiring.